Document is current
Any future updates will be listed below
-
Authors
Östör, Andrew https://orcid.org/0000-0002-7929-4827
Feist, Eugen
Sidiropoulos, Prodromos
Avouac, Jérôme
Rebella, Martin
Namas, Rajaie
Buttgereit, Frank
Conaghan, Philip G.
Romero, Ana B.
McDearmon-Blondell, Erin L.
Lagunes-Galindo, Ivan
Gao, Tianming
Kadakia, Aditi
Shaw, Tim
Attar, Suzan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04497597 at ClinicalTrials.govDocuments that mention this clinical trial
Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study
https://doi.org/10.1007/s40744-026-00826-5
AB0200 IMPROVEMENT OF SLEEP IMPAIRMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACHIEVING REMISSION OR PAIN RELIEVE WITH UPADACITINIB: RESULTS FROM THE POST-MARKETING OBSERVATIONAL SLEERA STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3146
POS0653 ACHIEVEMENT AND MAINTENANCE OF REMISSION WITH UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING: 1-YEAR OUTCOMES FROM THE UPHOLD STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.2238
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 18 November 2025
Accepted: 28 January 2026
First Online: 19 March 2026
Declarations
:
: Andrew Östör has served as a consultant and/or on advisory boards and/or undertaken clinical trials for AbbVie, GSK, Janssen, Lilly, Novartis, and Pfizer. Eugen Feist has received honoraria and research grants from AbbVie, BMS, Galapagos, Lilly, MSD, Novartis, Pfizer, Roche, and Sobi. Prodromos Sidiropoulos has received honoraria and research grants from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB through the University of Crete Special Account for Research. Jérôme Avouac has received honoraria from AbbVie, AstraZeneca, Biogen, BMS, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chugai, Sandoz, and Sanofi; and research grants from BMS, Fresenius Kabi, Galapagos, Novartis (Dreamer), and Pfizer (Passerelle). Martin Rebella has received honoraria and/or support to participate in academic events from AbbVie, Bayer, Pfizer, and Roche. Rajaie Namas has received speaker fees, research grants, and advisory honoraria from AbbVie. Frank Buttgereit has received consultancy fees, honoraria, travel expenses, and grant support from AbbVie, Amgen (Horizon Therapeutics), Grünenthal, Novartis, and Sparrow. Philip G. Conaghan has received speaker fees or consultancies from AbbVie, Formation Bio, Genascence, Grünenthal, GSK, Kolon TissueGene, Levicept, Lilly, Moebius, Novartis, Pacira, Stryker, and Takeda. Ana B. Romero, Erin L. McDearmon-Blondell, Ivan Lagunes-Galindo, Tianming Gao, Aditi Kadakia, and Tim Shaw are AbbVie employees and may own AbbVie stock or options. Suzan Attar has received speaker fees, research grants, and advisory honoraria from AbbVie, Amgen, AstraZeneca, BMS, Gilead, GSK, Hikma, Janssen, Lilly, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, and Takeda.
: The study was conducted according to the International Council on Harmonisation guidelines and the Helsinki Declaration of 1964 and its later amendments. The trial protocol was approved by independent ethics committees and institutional review boards at each study site. Written informed consent was provided by patients ahead of study screening.
